Gene therapy represents a promising therapeutic approach to treat various conditions, including cancer. Oftentimes, they utilize viral vectors to deliver nucleic acid cargo into target cells for gene silencing or editing profiting from the capacity of the virus to integrate in the host genome. However, inherent safety risks and limitations of viral vectors present barriers to further development and medical translation. To address this challenge, the SUPRO-GEN consortium aims to develop non-viral vectors based on positively charged polymers and lipids capable of electrostatically loading complex nucleic acids and targeted delivery to cancerous cells. To bring this technology to broad use and improve existing and future treatments, SUPRO-GEN researchers will extensively characterize and optimize engineered polyamine-lipid vectors for preclinical validation. These developments will further the targeting, potency, and efficacy capacities of cancer therapeutics.